Literature DB >> 10698037

No cyclicity in serum vascular endothelial growth factor during normal menstrual cycle but significant luteal phase elevation during an in vitro fertilization program.

L Unkila-Kallio1, P Vuorela-Vepsäläinen, A Tiitinen, E Halmesmäki, O Ylikorkala.   

Abstract

PROBLEM: To compare changes in serum vascular endothelial growth factor (VEGF) levels during normal and in vitro fertilization (IVF) cycles. METHOD OF STUDY: Ten healthy women with ovulatory cycles and 37 infertile women participating in an IVF program were followed by frequent serum samples and with VEGF measurements throughout their cycles.
RESULTS: Serum VEGF remained unchanged during the normal menstrual cycle, whereas the IVF program participants showed elevations in serum VEGF in the luteal phase of the cycle. When data from controls and patients were pooled, redundant midluteal VEGF level correlated with progesterone and with peak follicular phase estrogen level. The midluteal VEGF level in the IVF cycles was associated with body mass index (P < 0.01) and progesterone level (P < 0.05) by multiple regression. The 14 women conceiving tended to have higher VEGF levels than those failing to become pregnant.
CONCLUSIONS: The IVF program was associated with increased synthesis of VEGF either in the ovaries, endometrium, or at other sites and this may be of significance for the outcome of IVF.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10698037     DOI: 10.1111/j.8755-8920.2000.430105.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  4 in total

1.  Vascular repair after menstruation involves regulation of vascular endothelial growth factor-receptor phosphorylation by sFLT-1.

Authors:  M D Graubert; M A Ortega; B Kessel; J F Mortola; M L Iruela-Arispe
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  Effect of Intralipid infusion on peripheral blood T cells and plasma cytokines in women undergoing assisted reproduction treatment.

Authors:  Kerrie L Foyle; David J Sharkey; Lachlan M Moldenhauer; Ella S Green; Jasmine J Wilson; Cassandra J Roccisano; M Louise Hull; Kelton P Tremellen; Sarah A Robertson
Journal:  Clin Transl Immunology       Date:  2021-08-12

3.  Effects of EG-VEGF, VEGF and TGF-β1 on pregnancy outcome in patients undergoing IVF-ET treatment.

Authors:  Min-zhi Gao; Xiao-ming Zhao; Yi Lin; Zhao-gui Sun; Hui-qin Zhang
Journal:  J Assist Reprod Genet       Date:  2012-07-31       Impact factor: 3.412

4.  Circulating Vascular Endothelial Growth Factor and Soluble fms-Like Tyrosine Kinase-1 as Biomarkers for Endometrial Remodeling Across the Menstrual Cycle.

Authors:  Jessica R Zolton; Lindsey A Sjaarda; Sunni L Mumford; Elizabeth A DeVilbiss; Keewan Kim; Kerry S Flannagan; Jeannie G Radoc; Neil J Perkins; Robert M Silver; Jean Wactawski-Wende; Micah J Hill; Alan H DeCherney; Enrique F Schisterman
Journal:  Obstet Gynecol       Date:  2021-01-01       Impact factor: 7.623

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.